On Tuesday, Dyne Therapeutics Inc. (NASDAQ:DYN) announced new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) amenable to exon 51 ...
Shares of Dyne Therapeutics, Inc. DYN, a clinical-stage muscle disease company, tumbled 30.7% on two key announcements. The company announced that some of its senior executives have stepped down from ...
Dyne Therapeutics leverages its FORCE platform to target genetically driven muscle diseases. Read why I am bullish about DYN ...
Dyne Therapeutics, Inc. (DYN) is advancing the use of its FORCE platform to target skeletal muscle disorders. This would be with the use of modern oligonucleotide technology drugs like DYNE-101 and ...
Monday, Dyne Therapeutics Inc (NASDAQ:DYN) released clinical data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) and its ongoing Phase 1/2 ...
WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for ...
WALTHAM, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for ...
Dyne Therapeutics Inc. shares DYN jumped 40% premarket on Wednesday after the company released new data from trials of two investigational treatments for genetic muscle disorders. The experimental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results